5-异丙氧基-1H-吲哚 | 396091-50-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5-异丙氧基-1H-吲哚
• 中文别名: 5-(1-甲基乙氧基)-1H-吲哚
• 英文名称: 5-isopropoxyindole
• 英文别名: 5-Isopropoxy-1H-indole；5-propan-2-yloxy-1H-indole
• CAS: 396091-50-2
• 化学式: C₁₁H₁₃NO
• 分子量: 175.23
• InChiKey: VKHXUUUFVWIWHH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  25
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  5-异丙氧基-1H-吲哚 在 盐酸 、 三氯氧磷 作用下， 以 甲醇 为溶剂， 反应 6.75h， 生成 2-pentyl-1-[(E)-(5-propan-2-yloxy-1H-indol-3-yl)methylideneamino]guanidine
  参考文献：
  名称：

  The Serotonin 5-HT4 Receptor. 2. Structure-Activity Studies of the Indole Carbazimidamide Class of Agonists

  摘要：

  A number of substituted indole carbazimidamides were prepared and evaluated as 5-HT4 receptor agonists by using the isolated field-stimulated guinea pig ileum preparation. Their selectivity for the 5-HT4 receptor was established by examining their affinity for other 5-HT receptors using radioligand-binding techniques. Several selective and highly potent full as well as partial agonists emerged from this study. For example, 1b,d were found to be the most potent, full 5-HT4 receptor agonists described so far (EC(50) = 0.5 and 0.8 nM, respectively), being 6 and 4 times more potent than serotonin itself. On the other hand, 5b and 1h appeared as partial 5-HT4 receptor agonists in the nonstimulated guinea pig ileum preparation with potencies, evaluated against serotonin action, respectively similar (5b, K-i = 12 nM) to and 300-fold higher (1h, K-i = 0.04 nM) than serotonin.

  DOI：

  10.1021/jm00013a010
• 作为产物：
  描述：

  4-硝基间甲苯酚 在 palladium 10% on activated carbon 、 氢气 、 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 50.0~120.0 ℃ 、275.8 kPa 条件下， 反应 26.75h， 生成 5-异丙氧基-1H-吲哚
  参考文献：
  名称：

  蒙特胺合成研究：1,2-双（吲哚基）乙基肼片段的合成

  摘要：

  描述了在不常见的二聚生物碱生物胺中存在的具有完全取代模式的受保护的1,2-双（吲哚基）乙基肼的合成。使用Mitsunobu反应的变体将还原的偶氮二羧酸酯直接掺入胰多酚侧链中。将所得的氨基甲酸酯进行烷基化以得到天然产物的核心结构。

  DOI：

  10.1016/j.tetlet.2013.01.133

文献信息

• JAK INHIBITOR
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2108642A1

  公开（公告）日：2009-10-14

  A JAK inhibitor comprising, as an active ingredient, a nitrogen-containing heterocyclic compound represented by formula (I) wherein W represents a nitrogen atom or -CH-; X represents -C (=O) - or -CHR4- (wherein R4 represents a hydrogen atom, or the like); R1 represents the formula described below [wherein Q1 represents-CR8-(wherein R8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like); Q2 represents -NR15- (wherein R15 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like); and R5 and R6 may be the same or different and each represents a hydrogen atom, halogen, carboxy, substituted or unsubstituted lower alkyl, or the like], or the like; and R2 and R3 may be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like} or a pharmaceutically acceptable salt thereof.

  一种JAK抑制剂，其作为活性成分的是由式(I)表示的含氮杂环化合物 其中W代表氮原子或-CH-; X代表-C(=O)-或-CHR4-(其中R4代表氢原子或类似物); R1代表下述式[其中Q1代表-CR8-(其中R8代表氢原子、取代或未取代的较低烷基或类似物); Q2代表-NR15-(其中R15代表氢原子、取代或未取代的较低烷基或类似物);而R5和R6可以相同也可以不同，每个代表氢原子、卤素、羧基、取代或未取代的较低烷基或类似物，或类似物;而 R2和R3可以相同也可以不同，每个代表氢原子、卤素、取代或未取代的较低烷基或类似物}或其药学上可接受的盐。
• Anti-Viral Compounds
  申请人：DeGoey David A.

  公开号：US20100168138A1

  公开（公告）日：2010-07-01

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

  描述了一种有效抑制丙型肝炎病毒（“HCV”）复制的化合物。本发明还涉及制备这种化合物的方法、包含这种化合物的组合物，以及使用这种化合物治疗HCV感染的方法。
• Cp*Rh(III)-Catalyzed C–H Bond Difluorovinylation of Indoles with α,α-Difluorovinyl Tosylate
  作者：Lisheng Yang、Chunpu Li、Dechuan Wang、Hong Liu

  DOI：10.1021/acs.joc.9b00957

  日期：2019.6.7

  Unprecedented Rh(III)-catalyzed C–H bond difluorovinylation of indoles has been successfully developed, and this method provided an example of direct difluorovinylation reaction through C–H bond activation which was rarely reported. In this context, N-ethoxycarbamoyl served as the directing group and 2,2-difluorovinyl tosylates were used for the construction of difluorovinyl-substituted indoles. This

  前所未有的Rh（III）催化的吲哚CH-H键二氟乙烯基化已经成功开发，这种方法提供了一个通过C-H键激活直接二氟乙烯基化反应的例子，鲜有报道。在这种情况下，N-乙氧基氨基甲酰基用作导向基团，并且2，2-二氟乙烯基甲苯磺酸酯用于构建二氟乙烯基取代的吲哚。该方法提供了中等至良好产率的吲哚二氟乙烯基化的实用策略，并且其特征在于广泛的合成用途，温和的条件和高效率。
• Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1<i>H</i>-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT₆) Receptor Antagonist for Potential Treatment of Alzheimer’s Disease
  作者：Ramakrishna Nirogi、Anil Shinde、Rama Sastry Kambhampati、Abdul Rasheed Mohammed、Sangram Keshari Saraf、Rajesh kumar Badange、Thrinath Reddy Bandyala、Venugopalarao Bhatta、Kumar Bojja、Veena Reballi、Ramkumar Subramanian、Vijay Benade、Raghava Choudary Palacharla、Gopinadh Bhyrapuneni、Pradeep Jayarajan、Vinod Goyal、Venkat Jasti

  DOI：10.1021/acs.jmedchem.6b01662

  日期：2017.3.9

  04 nM) and selectivity over 100 target sites which include receptors, enzymes, peptides, growth factors, ion channels, steroids, immunological factors, second messengers, and prostaglandins. It has high selectivity over 5-HT2A receptor. It is orally bioavailable and brain penetrant with robust preclinical efficacy. The combination of 5al, donepezil, and memantine (triple combination) produces synergistic

  优化一系列新型的3-（哌嗪基甲基）吲哚衍生物作为5-羟基色胺-6受体（5-HT 6 R）拮抗剂可导致鉴定出1-[（（2-溴苯基）磺酰基] -5-甲氧基-3- [ （4-甲基-1-哌嗪基）甲基] -1 H-吲哚二甲酸酯一水合物（5al，SUVN-502）作为潜在治疗认知障碍的临床候选药物。它对人5-HT 6 R具有高亲和力（K i = 2.04 nM），对100个靶位具有选择性，这些靶位包括受体，酶，肽，生长因子，离子通道，类固醇，免疫学因子，第二信使和前列腺素。它具有超过5-HT 2A的高选择性受体。它具有口服生物利用度和脑渗透性，并具有强大的临床前功效。的组合5AL，多奈哌齐，美金刚和（三联组合）产生在腹侧海马乙酰胆碱的细胞外水平的协同效应。三联组合的临床前功效和对5-HT 2A受体的高选择性是区别特征，最终决定了5al的进一步开发。安全性和药代动力学的第一阶段评估已经完成，从而可以启动第二阶段概念验证研究。
• Synthesis and biological evaluation of novel <i>N</i>₁-phenylsulphonyl indole derivatives as potent and selective 5-HT₆R ligands for the treatment of cognitive disorders
  作者：Ramakrishna V. S. Nirogi、Thrinath Reddy Bandyala、Pamuletinarasimha Reddy Gangadasari、Mukkanti Khagga

  DOI：10.3109/14756366.2015.1103233

  日期：2016.11.1

  A series of 1-[3-(4-methyl piperazin-1-ylmethyl) phenylsulfonyl]-1H-indole and 1-[3-(4-ethyl piperazin-1-ylmethyl) phenylsulfonyl]-1H-indole derivatives were designed and synthesized as 5-HT6 receptor (5-HT6R) ligands. The lead compound 1-[4-methyl-3-(4-methyl piperazin-1-yl methyl) phenylsulfonyl]-1H-indole dihydrochloride (6b), in this series, has shown potent in vitro binding affinity, selectivity

  设计了一系列1- [3-（4-甲基哌嗪-1-基甲基）苯磺酰基] -1H-吲哚和1- [3-（4-乙基哌嗪-1-基甲基）苯基磺酰基] -1H-吲哚衍生物，合成为5-HT6受体（5-HT6R）配体。该系列的先导化合物1- [4-甲基-3-（4-甲基哌嗪-1-基甲基）苯磺酰基] -1H-吲哚二盐酸盐（6b）在体外显示出强大的结合亲和力，选择性，良好的药代动力学（PK）档案和认知动物模型中的活动。